Publications by authors named "B Yamout"

Claim this Profile
M
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.
Yi Chao Foong, Daniel Merlo, Melissa Gresle, Katherine Buzzard, Dana Horakova, Bassem Yamout

J Neurol Neurosurg Psychiatry· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert consensus on the clinical use of cladribine tablets for treating relapsing multiple sclerosis in the asia-pacific region.
Ho Jin Kim, Suzanne J Hodgkinson, Long-Sun Ro, Rocksy Fransisca V Situmeang, Sasitorn Siritho, Bassem Yamout

Mult Scler Relat Disord· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing reactivation of multiple sclerosis during treatment with natalizumab.
Nathaniel Lizak, Sifat Sharmin, Dana Horáková, Eva Kubala Havrdova, Sara Eichau, Bassem Yamout

Mult Scler· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry.
Enrique Gomez-Figueroa, Patricia Orozco-Puga, Cynthia Patricia Corona-Vázquez, Carlos Moreno-Bernardino, Graciela Elizabeth De la Mora-Landín, Bassem Yamout

Ther Adv Neurol Disord· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations for the use of off-label rituximab for the treatment of multiple sclerosis in low-resource settings.
Nick Rijke, Bassem I Yamout, Deanna Saylor, Francesco Nonino, Graziella Filippini

Mult Scler Relat Disord· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis